Compare HYFT & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HYFT | IMA |
|---|---|---|
| Founded | 1983 | 2019 |
| Country | United States | United States |
| Employees | 102 | 17 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.9M | 66.3M |
| IPO Year | N/A | N/A |
| Metric | HYFT | IMA |
|---|---|---|
| Price | $1.49 | $5.97 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 256.4K | 9.1K |
| Earning Date | 03-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $3.94 |
| 52 Week High | $3.00 | $17.50 |
| Indicator | HYFT | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 62.14 |
| Support Level | $1.40 | $6.10 |
| Resistance Level | $1.48 | $7.17 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 32.30 | 90.55 |
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.